Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Gradalis to Take Part in BIO Investor Forum in San Francisco

Posted on: 10 Oct 16

PR Newswire

DALLAS, Oct. 10, 2016

DALLAS, Oct. 10, 2016 /PRNewswire/ -- Gradalis, Inc., a clinical-stage biopharmaceutical company focused on developing Vigil® engineered autologous tumor cell (EATC) immunotherapy, will present at the BIO Investor Forum to be held October 18 -19, 2016 at the Westin St. Francis, San Francisco.  Mr. Sunil Joshi, President and Chief Executive Officer will present an overview of the Company's strategy and update on its lead clinical trials on October 18 at 1:30pm Pacific Time.  Mr. Joshi will be available for questions immediately following the presentation.

About Gradalis: Gradalis is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of novel proprietary personalized cellular immunotherapies to treat cancer. Gradalis operates a cGMP manufacturing facility in Carrolton, Texas. For more information about Gradalis, Inc. visit us at, follow us on Twitter or on Facebook.

About Vigil EATC: Vigil is an investigational cellular immunotherapy technology that combines the concepts of genetic engineering with the science of immuno-oncology, to enable an immune response to cancer cells. A patient's tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections. By utilizing the patient's own tumor as the antigen source, Vigil EATC is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient's unique tumor antigens.  Vigil EATC is being studied in Ewing's sarcoma and ovarian cancer as a single agent, and in breast cancer, non-small cell lung cancer and melanoma in combination with PD1 and PD-L1 inhibitors.  More information about these studies can be found at

Gradalis® and Vigil® are registered trademarks of Gradalis, Inc.

Beth Kriegel
Chief Financial Officer
Gradalis, Inc.
(214) 307-8203


To view the original version on PR Newswire, visit:

SOURCE Gradalis, Inc.

PR Newswire

Last updated on: 10/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.